Efficacy of miR-122 Nanoparticle Drug Delivery System on the Patients with Drug-Induced Liver Injury

Abstract

In order to explore the effect of MiR-122 nanoparticle (NP) drug delivery system (NPDDS) on the condition and curative effect of patients with drug-induced liver injury (DILI). The phosphate buffered saline solution was added to the solution of Monoammonium Glycyrrhizanate (MAG) NPs to make the suspension. Then, 50 μL of the MAG β-cyclodextrin star-shaped cationic polymer solution was added to the 100 μg/mL MiR-122 solution and form MAG/MiR-122 co-loaded NPs. 40 cases of acute DILI patients in hospital were selected as the research subjects. Control group, polymer group, drug-loaded group, and co-loaded group were set up, and fluorescence quantitative PCR was employed to measure the expression level of MiR-122 in the cells. The untreated DILI cells were set as control group, while the MAG/MiR-122 co-loaded NPs-treated DILI cells were set as treatment group. The treatment effects of the two groups were analyzed and compared. The results showed that the MAG/MiR co-loaded NPs prepared were of regular round shape and uniform particle size distribution. The expression of MiR-122 was low in control group, and its content in injured cells was extremely low. The expression of MiR-122 in the co-loaded group was superior to drug-loaded group. The effective rate of drug treatments in treatment group was significantly superior to control group, and the differences were substantial (P < 0.05). The number of red blood cells (RBC) of treatment group decreased notably relative to controls, while differences on white blood cells (WBC) and platelets (PLT) between two groups were not considerable (P > 0.05). In conclusion, MAG/MiR co-loaded NPs can effectively improve the therapeutic effect of DILI. Moreover, early DILI screening can be implemented by detecting the expression level of MiR-122 in the cells of DILI patients.